Search
Veliflapon
go.drugbank.com/drugs/DB16346InvestigationalVeliflapon is under investigation in clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina).
Categories: Heterocyclic Compounds, 2-RingBexotegrast
go.drugbank.com/drugs/DB16515InvestigationalPLN-74809 is a small-molecule that dually inhibits both α<sub>v</sub>β<sub>6</sub> and α<sub>v</sub>β<sub>1</sub> to treat both idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC … The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical
Synonyms: (2S)-4-(2-METHOXYETHYL-(4-(5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-2-YL)BUTYL)AMINO)-2-(QUINAZOLIN-4-YLAMINO)BUTANOIC ACID, (S)-4-[(2-Methoxyethyl)[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(quinazolin-4-yl)amino]butanoic acidDeucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigationalDeucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. … Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: SOTYKTU 6 mg film coated tablets, SOTYKTU® 6MG TABLETAS RECUBIERTASVecabrutinib
go.drugbank.com/drugs/DB16657InvestigationalVecabrutinib is under investigation in clinical trial NCT03037645 (Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers).
Categories: Heterocyclic Compounds, 1-RingIvarmacitinib
go.drugbank.com/drugs/DB16756InvestigationalIvarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions.
Categories: Janus Kinase 1, antagonists & inhibitorsTebipenem pivoxil
go.drugbank.com/drugs/DB16840ApprovedTebipenem pivoxil is an orally administered prodrug of tebipenem, a carbapenem antibacterial that kills bacteria by binding essential penicillin-binding proteins and disrupting cell wall biosynthesis. … severe or resistant Gram-negative infections but had until now been available only intravenously, meaning patients with resistant complicated urinary tract infections generally required hospitalization, a
Categories: MATE 1 Substrates, MATE 2 SubstratesTosufloxacin
go.drugbank.com/drugs/DB16850ExperimentalCategories: 4-Quinolones, Heterocyclic Compounds, 2-RingL-Acetylleucine
go.drugbank.com/drugs/DB16956ApprovedInvestigational[A264439] Observational studies in patients with Niemann-Pick disease type C (NPC) suggested a beneficial symptomatic as well as neuroprotective disease-modifying effect of the DL-form of N-acetylleucine … Levacetylleucine (L-acetylleucine) is a modified acetylated derivative of the amino acid [leucine]. The racemic (i.e. DL-) form has been available in France since 1957 for the treatment of vertigo.
Categories: P-glycoprotein inhibitorsSynonyms: (s)-2-acetamido-4-methylpentanoic acid, L-leucine, n-acetyl-NP-51
go.drugbank.com/drugs/DB16995InvestigationalSynonyms: 3-pyridinecarboximidamide, n-(2-hydroxy-3-(1-piperidinyl)propoxy)-, (+/-)-o-(3-piperidino-2-hydroxy-1-propyl)nicotinic acid amidoximeCategories: Heterocyclic Compounds, 1-RingNutlin-3
go.drugbank.com/drugs/DB17039ExperimentalNutlin-3 is a small molecule inhibitor that targets p53-Mdm2 interaction.[A253057]
Categories: Heterocyclic Compounds, 1-RingSynonyms: 2-piperazinone, 4-(((4r,5s)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-(4-methoxy-2-(1-methylethoxy)phenyl)-1h-imidazol-1-yl)carbonyl)-, rel-, Nutlin-3